HK1215594A1 - 用於指示侵襲性前列腺癌的存在或不存在的方法 - Google Patents

用於指示侵襲性前列腺癌的存在或不存在的方法

Info

Publication number
HK1215594A1
HK1215594A1 HK16103559.9A HK16103559A HK1215594A1 HK 1215594 A1 HK1215594 A1 HK 1215594A1 HK 16103559 A HK16103559 A HK 16103559A HK 1215594 A1 HK1215594 A1 HK 1215594A1
Authority
HK
Hong Kong
Prior art keywords
indicating
prostate cancer
aggressive prostate
aggressive
cancer
Prior art date
Application number
HK16103559.9A
Other languages
English (en)
Inventor
Henrik Grnberg
Martin Eklund
Original Assignee
Phadia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phadia Ab filed Critical Phadia Ab
Publication of HK1215594A1 publication Critical patent/HK1215594A1/zh

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
HK16103559.9A 2012-11-20 2016-03-29 用於指示侵襲性前列腺癌的存在或不存在的方法 HK1215594A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1251312 2012-11-20
SE1350600 2013-05-16
PCT/EP2013/074259 WO2014079865A1 (en) 2012-11-20 2013-11-20 Method for indicating a presence or non-presence of aggressive prostate cancer

Publications (1)

Publication Number Publication Date
HK1215594A1 true HK1215594A1 (zh) 2016-09-02

Family

ID=49619938

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103559.9A HK1215594A1 (zh) 2012-11-20 2016-03-29 用於指示侵襲性前列腺癌的存在或不存在的方法

Country Status (15)

Country Link
US (1) US10431326B2 (zh)
EP (2) EP3327146A1 (zh)
JP (2) JP2016503301A (zh)
KR (1) KR20150110477A (zh)
AU (1) AU2013349801B2 (zh)
BR (1) BR112015011359B1 (zh)
CA (2) CA3092807C (zh)
DK (1) DK2922967T3 (zh)
ES (1) ES2667326T3 (zh)
HK (1) HK1215594A1 (zh)
IL (1) IL238724A0 (zh)
MY (1) MY182773A (zh)
RU (1) RU2675370C2 (zh)
WO (1) WO2014079865A1 (zh)
ZA (1) ZA201503460B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI638277B (zh) 2012-03-05 2018-10-11 Opko診斷法有限責任公司 用於確定前列腺癌相關事件之機率之分析系統及方法
JP2016508026A (ja) 2012-11-20 2016-03-17 ファディア・アクチボラゲットPhadia AB 前立腺癌を有する個体の予後診断方法
EP4220170A3 (en) 2014-03-11 2023-12-13 Phadia AB Method for detecting a solid tumor cancer
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
US9858665B2 (en) * 2015-04-03 2018-01-02 Regents Of The University Of Minnesota Medical imaging device rendering predictive prostate cancer visualizations using quantitative multiparametric MRI models
AU2016254127B2 (en) * 2015-04-29 2022-05-26 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2017164699A1 (ko) * 2016-03-24 2017-09-28 서울대학교병원 (분사무소) 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
ES2688213T3 (es) * 2016-07-15 2018-10-31 Proteomedix Ag Método para detectar proteínas en muestras humanas y usos de dichos métodos
JP7138112B2 (ja) * 2017-02-01 2022-09-15 ファディア・アクチボラゲット 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
KR102093453B1 (ko) * 2018-01-08 2020-03-25 (주)인실리코젠 체형 및 대사 감수성 snp 마커 및 진단정보 제공방법
WO2019144112A1 (en) 2018-01-22 2019-07-25 Phadia Ab Method for the harmonization of assay results
IT201800021394A1 (it) * 2018-12-28 2020-06-28 Daniela Terracciano Metodo in vitro per la diagnosi del cancro alla prostata
US11633146B2 (en) 2019-01-04 2023-04-25 Regents Of The University Of Minnesota Automated co-registration of prostate MRI data
US11631171B2 (en) 2019-01-10 2023-04-18 Regents Of The University Of Minnesota Automated detection and annotation of prostate cancer on histopathology slides
CN109628564B (zh) * 2019-02-25 2022-02-01 北京市理化分析测试中心 一种用于检测snp多态性的引物组和利用引物组检测snp多态性的方法
KR102068667B1 (ko) * 2019-02-28 2020-01-21 주식회사 프로카젠 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371654B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102068666B1 (ko) * 2019-02-28 2020-02-11 주식회사 프로카젠 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371655B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
IT202000029948A1 (it) * 2020-12-04 2022-06-04 Nib Biotec S R L Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età
GB2599198B (en) * 2021-06-15 2022-12-07 A3P Biomedical Ab A method for determining an appropriate time interval for further diagnostic testing for prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219840A1 (en) 2002-05-24 2003-11-27 Mikolajczyk Stephen D. Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
WO2010081240A1 (en) * 2009-01-19 2010-07-22 Miraculins Inc. Diagnostic assays for prostate cancer using psp94 and psa biomarkers
WO2010093939A2 (en) 2009-02-12 2010-08-19 Dana-Farber Cancer Institute, Inc. Predicting and treating prostate cancer
WO2011150515A1 (en) * 2010-06-01 2011-12-08 Universite Laval Prognostic markers for prostate cancer recurrence
EP2611943B1 (en) 2010-09-03 2017-01-04 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) * 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
EP2850432A2 (en) 2012-05-16 2015-03-25 Phadia AB Method for indicating the presence or non-presence of prostate cancer
JP2016508026A (ja) 2012-11-20 2016-03-17 ファディア・アクチボラゲットPhadia AB 前立腺癌を有する個体の予後診断方法

Also Published As

Publication number Publication date
US10431326B2 (en) 2019-10-01
KR20150110477A (ko) 2015-10-02
BR112015011359A2 (pt) 2017-07-11
RU2675370C2 (ru) 2018-12-19
MY182773A (en) 2021-02-05
BR112015011359A8 (pt) 2019-10-01
CA3092807A1 (en) 2014-05-30
AU2013349801B2 (en) 2019-03-07
IL238724A0 (en) 2015-06-30
EP2922967A1 (en) 2015-09-30
WO2014079865A1 (en) 2014-05-30
BR112015011359B1 (pt) 2022-12-06
RU2015124054A (ru) 2017-01-10
ZA201503460B (en) 2018-11-28
CA2891392C (en) 2020-11-03
CA3092807C (en) 2024-02-27
EP3327146A1 (en) 2018-05-30
EP2922967B1 (en) 2018-01-03
CN105051206A (zh) 2015-11-11
JP2019049559A (ja) 2019-03-28
JP2016503301A (ja) 2016-02-04
AU2013349801A1 (en) 2015-05-28
US20150317431A1 (en) 2015-11-05
DK2922967T3 (en) 2018-04-16
CA2891392A1 (en) 2014-05-30
ES2667326T3 (es) 2018-05-10

Similar Documents

Publication Publication Date Title
HK1215594A1 (zh) 用於指示侵襲性前列腺癌的存在或不存在的方法
IL237791B (en) A method for treating cancer
IL228538B (en) A method for identifying cancers that may respond to immunoprecipitation against folr1
SG11201503893RA (en) Method of treating cancer
EP2815070A4 (en) CALIBRATION BASED ON AN INVERSION OF ELECTROMAGNETIC TOOLS IN THE BOTTOM OF A HOLE
SG11201510210XA (en) Methods for detecting prostate cancer
EP2698634A4 (en) BIOMARKER FOR BREAST CANCER
EP2668295A4 (en) METHODS OF DETECTING LUNG CANCER
EP2876447A4 (en) METHOD OF DETECTING CANCER
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
EP2851688A4 (en) MARKER FOR THE DETECTION OF PANCREATIC CANCER
EP2686447A4 (en) PROGNOSTIC MARKER SETS FOR PROSTATE CANCER
EP2876446A4 (en) METHOD OF DETECTING CANCER
HK1220253A1 (zh) 診斷前列腺癌症的方法
IL232493A0 (en) A method for quantifying cancer treatment
EP2699699A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2894477A4 (en) METHOD FOR DETECTION OF BREAST CANCER
GB2510539B (en) Biomarkers of cancer
HK1200502A1 (zh) 判定患者前列腺癌預測的方法
EP2771695A4 (en) METHOD OF DETECTION OF BREAST CANCERS
EP2888594A4 (en) METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER
EP2882869A4 (en) PROSTATE CANCER GENE EXPRESSION PROFILES
GB201004304D0 (en) Biomarkers for prostate cancer
GB201218219D0 (en) Nucleic acid biomarkers for prostate cancer
IL229109A0 (en) Cancer diagnosis